12 citations
,
December 2019 in “International Journal of Molecular Medicine” This study found that human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) significantly prevented hair loss induced by dexamethasone in a mouse model and enhanced cell proliferation in human hair follicle cells, suggesting a protective effect against stress-related hair loss.
January 2019 in “Journal of Clinical Dermatology” This study found that a hair tonic containing a human umbilical cord blood mesenchymal stem cell-derived conditioned medium significantly increased hair density, thickness, and growth rate in patients with androgenetic alopecia.
January 2019 in “대한피부과학회지” In this study, a hair tonic containing human umbilical cord blood mesenchymal stem cell-derived conditioned medium significantly increased hair density, thickness, and growth rate in patients with androgenetic alopecia.
11 citations
,
August 2021 in “Stem Cell Research & Therapy” This study found that coadministration of pimecrolimus may interfere with the therapeutic efficacy of mesenchymal stem cell therapy in atopic dermatitis.
November 2024 in “Cells Tissues Organs” This study found that human umbilical cord blood-derived mesenchymal stem cells (HUCB-MSCs) improved hair growth and follicle structure in male rats with androgenic alopecia, achieving better results and longer-lasting effects compared to minoxidil treatment, with no observed side effects.